文献速递糖尿病

基于临床变量的2型糖尿病亚型复制与交叉验证:IMI-RHAPSODY研究

Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study.
PubMed 文献 · Diabetologia · 2021-06-10

该研究在三个独立队列共15940人中,基于年龄、BMI、HbA1c、C肽和HDL-胆固醇进行聚类,复制并交叉验证了既往基于HOMA指标的2型糖尿病亚型。结果识别出五个聚类,可映射回原始ANDIS四个聚类,其中SIDD、SIRD和MOD映射灵敏度较高,MARD则分化为高HDL-胆固醇的MDH和MD两个较温和聚类。SIDD进展至胰岛素需求最快,MDH最慢。

要点

  • 基于C肽和HDL-胆固醇的聚类可复制基于HOMA2的2型糖尿病亚型,SIDD、SIRD和MOD映射灵敏度高。
  • MARD聚类可拆分为高HDL-胆固醇的MDH和無极端特征的MD两个较温和聚类。
  • SIDD患者进展至胰岛素需求最快,MDH最慢。

核心结论

  • 基于临床易测变量(年龄、HbA1c、HDL-胆固醇、BMI和C肽)的聚类可产生代表原始ANDIS聚类且跨队列稳定的信息性亚型。
  • 加入HDL-胆固醇后,基于HOMA2的MARD聚类可识别出高HDL且血糖恶化极慢的亚组。

研究设计与样本

  • 在三个独立队列共15940人中,基于年龄、BMI、HbA1c、随机或空腹C肽及HDL-胆固醇进行聚类。
  • 聚类与基于HOMA指标的原始聚类进行交叉验证,并通过各队列聚类中心重新分配个体进行队列间交叉验证。
  • 比较各聚类至胰岛素需求的时间。

主要发现

  • 识别出五个不同的2型糖尿病聚类,可映射回原始四个ANDIS聚类。
  • 使用C肽和HDL-胆固醇替代HOMA2-B和HOMA2-IR时,三个聚类以高灵敏度(80.6-90.7%)映射至既往识别的SIDD、SIRD和MOD聚类。
  • 既往ANDIS的MARD聚类可映射至本研究的两个较温和组:高HDL-胆固醇的MDH聚类和无极端特征的MD聚类;两者合并后与MARD映射良好(灵敏度79.1%)。
  • 队列间交叉验证中,SIDD和MDH聚类交叉验证良好,灵敏度范围73.3%至97.1%;SIRD和MD灵敏度较低,范围36.1%至92.3%,个体在SIRD与MD间转换。
  • SIDD聚类患者进展至胰岛素需求最快,MDH聚类最慢。

临床怎么用

  • 临床可基于年龄、HbA1c、HDL-胆固醇、BMI和C肽等易测变量对2型糖尿病进行亚型划分,以识别进展风险不同的患者。
  • SIDD聚类患者胰岛素需求进展最快,MDH聚类最慢,提示可根据聚类评估疾病进展速度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Five clusters based on clinical characteristics have been suggested as diabetes subtypes: one autoimmune and four subtypes of type 2 diabetes. In the current study we replicate and cross-validate these type 2 diabetes clusters in three large cohorts using variables readily measured in the clinic. METHODS: In three independent cohorts, in total 15,940 individuals were clustered based on age, BMI, HbA1c, random or fasting C-peptide, and HDL-cholesterol. Clusters were cross-validated against the original clusters based on HOMA measures. In addition, between cohorts, clusters were cross-validated by re-assigning people based on each cohort's cluster centres. Finally, we compared the time to insulin requirement for each cluster. RESULTS: Five distinct type 2 diabetes clusters were identified and mapped back to the original four All New Diabetics in Scania (ANDIS) clusters. Using C-peptide and HDL-cholesterol instead of HOMA2-B and HOMA2-IR, three of the clusters mapped with high sensitivity (80.6-90.7%) to the previously identified severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD) and mild obesity-related diabetes (MOD) clusters. The previously described ANDIS mild age-related diabetes (MARD) cluster could be mapped to the two milder groups in our study: one characterised by high HDL-cholesterol (mild diabetes with high HDL-cholesterol [MDH] cluster), and the other not having any extreme characteristic (mild diabetes [MD]). When these two milder groups were combined, they mapped well to the previously labelled MARD cluster (sensitivity 79.1%). In the cross-validation between cohorts, particularly the SIDD and MDH clusters cross-validated well, with sensitivities ranging from 73.3% to 97.1%. SIRD and MD showed a lower sensitivity, ranging from 36.1% to 92.3%, where individuals shifted from SIRD to MD and vice versa. People belonging to the SIDD cluster showed the fastest progression towards insulin requirement, while the MDH cluster showed the slowest progression. CONCLUSIONS/INTERPRETATION: Clusters based on C-peptide instead of HOMA2 measures resemble those based on HOMA2 measures, especially for SIDD, SIRD and MOD. By adding HDL-cholesterol, the MARD cluster based upon HOMA2 measures resulted in the current clustering into two clusters, with one cluster having high HDL levels. Cross-validation between cohorts showed generally a good resemblance between cohorts. Together, our results show that the clustering based on clinical variables readily measured in the clinic (age, HbA1c, HDL-cholesterol, BMI and C-peptide) results in informative clusters that are representative of the original ANDIS clusters and stable across cohorts. Adding HDL-cholesterol to the clustering resulted in the identification of a cluster with very slow glycaemic deterioration.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Slieker RC, Donnelly LA, Fitipaldi H, et al. Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study. Diabetologia. 2021. PMID: 34110439. doi:10.1007/s00125-021-05490-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。